Personalized Medicine Approaches Continue to Gain Steam in BRAF/NRAS+ Metastatic Melanoma

Source: OncLive, February 2022

Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.

The field of metastatic melanoma is continuing to develop novel targeted therapies that will further personalize treatment options to individuals based on the molecular characteristics of their disease, said Meredith McKean, MD, MPH, who highlighted that these developments further underscore the importance of broad molecular testing with next-generation sequencing (NGS).

“In oncology, we are continuing to evolve toward more personalization. That is in correlation with clinical trials that provide more opportunities for our patients. Trying to match the right patient to the right drug is really what we should be doing in oncology,” McKean said.

READ THE ORIGINAL FULL ARTICLE